Literature DB >> 1090988

Aerosol chemotherapy in bronchopulmonary candidiasis.

A Oehling, M Giron, M L Subira.   

Abstract

One of the most frequent complications encountered in non-specific respiratory pathology of recent years is overinfection by Candida albicans. An important contributive factor is the recent massive antibiotherapy, above all with tetracyclines, favouring this overinfection. Since at present the treatment of bronchopulmonary processes is difficult owing to the lack of an effective oral or parenteral therapy, a study was carried out of 33 patients treated with nystatin and amphotericin B in aerosol form, with 3-4 sessions of treatment per day, during a minimum of 10 days. At each session either 50,000 U of nystatin or 5 mg of amphotericin B were administered. The results obtained showed that after treatment, C. albicans was no longer present in the sputum of 84% of cases treated. In view of these results it is considered that - at present - the two most suitable substances for the treatment of pulmonary candidiases are nystatin and amphotericin B in aerosol form.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090988     DOI: 10.1159/000193647

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

1.  New nystatin polymeric complexes and their in vitro antifungal evaluation in a model study with Fusarium oxysporum.

Authors:  Ekatherina Charvalos; Aristeidis Tsatsakis; Manolis Tzatzarakis; George Dolapsakis; John Stiakakis
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

Review 2.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

3.  Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin.

Authors:  S Rodenhuis; F Beaumont; H F Kauffman; H J Sluiter
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

4.  Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.

Authors:  T L Wallace; V Paetznick; P A Cossum; G Lopez-Berestein; J H Rex; E Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.

Authors:  E Martin; A Stüben; A Görz; U Weller; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

6.  Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia.

Authors:  B Hertenstein; W V Kern; T Schmeiser; M Stefanic; D Bunjes; M Wiesneth; J Novotny; H Heimpel; R Arnold
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.